Table 2.
Changes of BPRS total scores of patients who fully or partly maintained the initial treatment from baseline to endpoint among the five kinds of antipsychotic drugs
| Groups | N | BPRS total score at baseline | BPRS total score at endpoint | Deduction rate of BPRS total score |
|---|---|---|---|---|
| Aripiprazole | 23 | 54.00 ± 10.39 | 29.96 ± 9.05 | 0.44 ± 0.13 |
| Risperidone | 23 | 56.04 ± 10.39 | 24.87 ± 7.05 | 0.55 ± 0.12ab |
| Quetiapine | 27 | 58.48 ± 11.16 | 28.74 ± 6.21 | 0.50 ± 0.11 |
| Olanzapine | 21 | 53.10 ± 11.5 | 26.90 ± 4.75 | 0.47 ± 0.15 |
| Ziprasidone | 7 | 58.71 ± 14.59 | 25.86 ± 4.91 | 0.54 ± 0.13 |
| F value | 0.97 | 1.95 | 2.97 | |
| P value | > 0.05 | > 0.05 | 0.023 |
Deduction rate of BPRS score: (baseline BPRS total scores − post-treatment BPRS total scores)/baseline BPRS total scores. Values are represented as mean ± SD
N: number of patients
aComparison of risperidone with aripiprazole, P < 0.01
bComparison of risperidone with olanzapine, P < 0.05